web analytics
25.6 C
Munich
Wednesday, August 10, 2022

TAG

NWBO

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Heats Up as DCVax®-L Proves Safe & Effective While Sawston Facility Applies for Commercial Manufacturing License for Cellular Therapies

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) has made a significant move northbound out of the trading channel where it was trading for the past few...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Looking to Breakout After Phase 3 Clinical Trial of DCVax®-L for GBM Showed Improved Overall Survival & Favorable Safety...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is looking to break north over $0.74 out its current trading channel after recently being decimated due to Adam...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Coming Back After Major Short Attack While Biotech Reports Primary and Secondary Endpoints Met for DCVax®-L with Excellent Safety...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is moving northbound once again after a major short attack with at least 15 million shares sold short decimated...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Bull Run as Biotech Set to Release Phase III Top Line Data for DCVax®-L May 10 / Dr. Linda...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is tearing up the charts making a powerful run northbound easily eclipsing the $1.50 mark where the stock had...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is Heating Up as Biotech Begins Production of Dendritic Cell Cancer Vaccine at Sawston Facility & Phase III Top...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is one exciting biotech that has given up some gains since hitting highs of $2.50 per share but not...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Major Move Northbound as Sawston Facility is Licensed by (HTA) and (MHRA) & Biotech Awaits Imminent Phase III Top...

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is making a powerful run up the charts ever since reversing off $0.59 lows halfway through December. Volume has...

Latest news